Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells

被引:80
|
作者
Blagosklonny, MV
Giannakakou, P
Wojtowicz, M
Romanova, LY
Ain, KB
Bates, SE
Fojo, T
机构
[1] NCI, Med Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Genet Lab, NIH, Bethesda, MD 20892 USA
[3] Univ Kentucky, Med Ctr, Thyroid Canc Res Lab, Vet Adm Med Ctr, Lexington, KY 40536 USA
来源
关键词
D O I
10.1210/jc.83.7.2516
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We investigated the p53 status and the ability of exogenous wildtype (wt) p53 to affect chemosensitivity in three anaplastic thyroid carcinoma cell lines (BHT-101, SW-1736, and KAT-4). All three cell lines had nonfunctional p53. Treatment with mitomycin C or adriamycin did not result in accumulation of p53 or induction of p21(WAF1/CIP1) or Mdm-2 and did not cause Rb dephosphorylation. BHT-101 and KAT-4 cells had mutant p53. SW-1736 cells were functionally mutant because of marked down-regulation of wt p53 messenger ribonucleic acid, representing a novel mechanism of p53 dysfunction. Infection with a p53-expressing adenovirus (Ad-p53) induced high levels of p21 and Mdm-2 proteins. In BHT-101 cells, induction of p21 and Mdm-2 was evident 10 h after infection. In KAT-4 cells, induction of p21 and Mdm-2 was observed 1 day after infection, and continued to increase over the ensuing 24 h. SW-1736 cells demonstrated intermediate kinetics. Sensitivity to the cytotoxic effect of Ad-p53 paralleled the kinetics of p21/Mdm-2 induction. BHT-101 cells were most sensitive to killing by Ad-p53, with an IC,, of less than 2 multiplicity of infection; SW-1736 cells were intermediate in sensitivity; KAT-B cells were resistant. All three cell lines became more sensitive to adriamycin after wt p53 expression, with a 10-fold decrease in IC,, values. The latter observation may make a combination of wt p53 and chemotherapeutic drugs an attractive modality for treating anaplastic thyroid cancer.
引用
收藏
页码:2516 / 2522
页数:7
相关论文
共 50 条
  • [1] In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug
    Blagosklonny, MV
    ElDeiry, WS
    INTERNATIONAL JOURNAL OF CANCER, 1996, 67 (03) : 386 - 392
  • [2] Mitomycin C and cisplatin enhanced the antitumor activity of p53-expressing adenovirus in cervical cancer cells
    Huang, TG
    Ip, SM
    Yeung, WSB
    Ngan, HYS
    CANCER INVESTIGATION, 2001, 19 (04) : 360 - 368
  • [3] The paradigm of mutant p53-expressing cancer stem cells and drug resistance
    Shetzer, Yoav
    Solomon, Hilla
    Koifman, Gabriela
    Molchadsky, Alina
    Horesh, Stav
    Rotter, Varda
    CARCINOGENESIS, 2014, 35 (06) : 1196 - 1208
  • [4] mTOR inhibitor augments the antitumor effect of p53-expressing oncolytic adenovirus in human neuroblastoma cells
    Tanimoto, Terutaka
    Tazawa, Hiroshi
    Noso, Hiroshi
    Tani, Morimichi
    Oyama, Takanori
    Urata, Yasuo
    Kagawa, Shunsuke
    Noda, Takuo
    Fujiwara, Toshiyoshi
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Inhibitory Effects of 5-Aza-2′-Deoxycytidine and Trichostatin A in Combination with p53-Expressing Adenovirus on Human Laryngocarcinoma Cells
    Jiang, Ling-yan
    Lian, Meng
    Wang, Hong
    Fang, Ju-gao
    Wang, Qi
    CHINESE JOURNAL OF CANCER RESEARCH, 2012, 24 (03) : 232 - 237
  • [7] Pifithrin-α enhancing anticancer effect of topotecan on p53-expressing cancer cells
    Guo, Jianli
    Tang, Qin
    Wang, Qingling
    Sun, Wenhui
    Pu, Zhongji
    Wang, Jingyun
    Bao, Yongming
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 128 : 61 - 72
  • [9] p53-expressing conditionally replicative adenovirus CNHK500-p53 against hepatocellular carcinoma in vitro
    Zhao, Hong-Chuan
    Zhang, Qi
    Yang, Yang
    Lu, Min-Qiang
    Li, Hua
    Xu, Chi
    Chen, Gui-Hua
    WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (05) : 683 - 691
  • [10] Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells
    Yoshitsugu Horio
    Yoshinori Hasegawa
    Yoshitaka Sekido
    Masahide Takahashi
    Jack A Roth
    Kaoru Shimokata
    Cancer Gene Therapy, 2000, 7 : 537 - 544